Hanmi Pharmaceutical stock (KR7128940004): US oncology exposure via licensing deals

Hanmi Pharmaceutical remains in focus as its partnered oncology drug Rolvedon builds out the US market and the company emphasizes overseas licensing. We outline the Korean drug maker’s model, key revenue drivers and relevance for US healthcare investors.

Hanmi Pharmaceutical has drawn renewed attention from global healthcare investors as its partnered oncology drug Rolvedon continues to expand in the US market and the company reiterates its strategy of developing innovative therapies for out-licensing to multinational partners. Rolvedon, based on eflapegrastim developed by Hanmi, is marketed in the United States by Spectrum Pharmaceuticals, which was acquired by Assertio in 2023 and later sold to Zydus Lifesciences, highlighting the strategic value of Hanmi’s pipeline according to Citeline as of 05/09/2024.

While Hanmi Pharmaceutical’s shares trade in Seoul rather than on US exchanges, the company’s licensing-heavy model means a notable portion of its growth prospects depends on commercial execution in the United States and other major pharmaceutical markets. For US investors following global oncology and metabolic therapy pipelines, Hanmi represents an example of how Korean drug developers are increasingly integrated into the US biopharma ecosystem through partnerships and royalty deals, as discussed by regional industry coverage in Asia-focused financial media such as FirstWord Pharma as of 03/04/2024.

As of: 16.05.2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: Hanmi Pharm
• Sector/industry: Pharmaceuticals and biotechnology
• Headquarters/country: Seoul, South Korea
• Core markets: South Korea domestic market; partnered products in the US, Europe and other global regions
• Key revenue drivers: Prescription drugs in Korea, milestone and royalty income from licensed-out drug candidates
• Home exchange/listing venue: Korea Exchange (KOSPI), ticker often quoted as 128940
• Trading currency: Korean won (KRW)

Hanmi Pharmaceutical: core business model

Hanmi Pharmaceutical is a South Korean research-driven drug maker focusing on prescription medicines and novel drug candidates across oncology, diabetes, obesity and other metabolic disorders. It operates as part of the Hanmi group structure under holding company Hanmi Science, while Hanmi Pharmaceutical is the main operating entity for R&D-intensive activities and branded prescription sales domestically. The company combines its own commercial footprint in Korea with a partnership strategy for global markets according to its investor materials and transaction history referenced by Citeline as of 05/09/2024.

The core of Hanmi’s model is to advance innovative candidates through early and mid-stage clinical development and then license them to larger multinational partners for late-stage trials, regulatory filings and commercialization in the US and other key territories. This approach allows Hanmi to leverage larger partners’ commercial infrastructure while focusing its own resources on discovery, early clinical work and its domestic marketing organization. Deals have historically involved upfront payments, development and sales milestones, and eventual royalty streams, creating a portfolio of contingent income sources that depend on downstream success.

Domestically, Hanmi maintains a broad portfolio of established prescription drugs, including therapies in endocrinology, cardiovascular disease and infectious disease. These products generate recurring revenue that helps fund the company’s R&D activities. At the same time, Hanmi continues to invest heavily in biologics and long-acting formulations using proprietary platform technologies, aiming to differentiate its pipeline in crowded categories such as GLP-1-based treatments for obesity and diabetes. This dual model of established brands plus high-risk, high-reward innovation underpins the company’s long-term strategy, as outlined in its presentations and reflected in the focus of global collaboration news tracked by FirstWord Pharma as of 03/04/2024.

Main revenue and product drivers for Hanmi Pharmaceutical

The most visible link between Hanmi and the US market today is Rolvedon (eflapegrastim-xnst), a long-acting granulocyte colony-stimulating factor indicated to reduce the incidence of febrile neutropenia in adult patients with non-myeloid malignancies receiving myelosuppressive chemotherapy. Hanmi originally developed eflapegrastim and licensed the asset to Spectrum Pharmaceuticals for development and commercialization in North America. Following Assertio’s acquisition of Spectrum and the subsequent sale of Rolvedon rights to Zydus Lifesciences, Hanmi’s asset now sits within a broader growth platform targeting oncology-related supportive care in the US, according to Citeline as of 05/09/2024.

For Hanmi, the commercial rollout of Rolvedon translates into potential milestone receipts and, over time, royalty income tied to US sales. Citeline’s analysis in May 2024 suggested that Rolvedon’s US revenue might peak later in the decade as competition and treatment patterns evolve, illustrating how Hanmi’s economic participation is leveraged to US oncology market dynamics. While Hanmi does not directly market the drug in the United States, its financial performance can be indirectly influenced by uptake trends among US oncologists, reimbursement conditions and competitive responses from other long-acting G-CSF products.

Beyond Rolvedon, Hanmi has signed multiple licensing agreements over the years in areas such as diabetes and obesity, though not all programs have progressed smoothly. Some collaborations have been restructured or terminated, a common pattern in high-risk biopharmaceutical development. Even so, the company’s pipeline emphasizes long-acting formulations and combination therapies targeting major chronic diseases where US market demand is large and innovation remains a key differentiator. For example, global interest in incretin-based therapies for obesity continues to grow, and Korean drug developers, including Hanmi, are working on differentiated candidates that could eventually be partnered with US or European pharmaceutical companies, as reflected in region-wide coverage of Asian metabolic pipelines by outlets such as FirstWord Pharma as of 03/04/2024.

Hanmi’s domestic branded portfolio remains important as a stabilizing factor. Korean prescription drug sales generate steady cash flow and help mitigate the inherent volatility of milestone-driven revenue. Many of these products address widely prevalent diseases, including hypertension and diabetes, aligning Hanmi with national healthcare priorities in Korea. While specific product-level revenue figures are typically disclosed in the company’s periodic reports and earnings releases, the overarching pattern is that domestic sales provide a base layer of revenue, on top of which milestone, licensing and royalty income from international collaborations can add cyclical upside.

Industry trends and competitive position

Hanmi operates within a highly competitive global pharmaceutical landscape in which large US and European firms dominate late-stage development and commercialization, while smaller innovators drive much of the early-stage pipeline. Korean companies have increasingly sought to position themselves as innovation partners, supplying differentiated assets that can be scaled globally through partnerships. This is evident not only in Hanmi’s oncology and metabolic programs but also in moves by related Korean healthcare firms to expand their global footprint, such as affiliate JVM’s efforts to build an Asia hub for automated pharmacy systems in Suzhou, which illustrate how the broader Hanmi ecosystem is oriented toward international growth according to The Chosun Ilbo as of 05/15/2026.

In oncology supportive care, Rolvedon competes with well-established long-acting G-CSF agents, and its commercial trajectory depends on demonstrating meaningful advantages in efficacy, safety, convenience or cost. US payers, including commercial insurers and government programs, play a crucial role in formulary position and access, which in turn shapes the royalties Hanmi may receive from its partners. Citeline’s 2024 deal analysis noted that Rolvedon offers Zydus an entry point into the US oncology market, with peak sales expectations tempered by competition and changing treatment standards, implying that the asset’s contribution to Hanmi will likely be important but not transformative in isolation, as discussed by Citeline as of 05/09/2024.

In metabolic disease and obesity, Hanmi faces intense competition from global leaders that have already launched blockbuster GLP-1 receptor agonists and combination therapies. However, the enormous and still growing size of the market leaves room for differentiated entrants, especially if they offer improved tolerability, weight-loss efficacy or oral dosing options. Korean developers, including Hanmi, may find niches where they can contribute novel mechanisms or more convenient formulations that can later be licensed to large pharma partners. The ability of Hanmi to secure favorable licensing terms and maintain robust R&D productivity will shape its competitive position relative to both domestic peers and international biotech companies.

Why Hanmi Pharmaceutical matters for US investors

Although Hanmi Pharmaceutical shares trade in Korean won on the Korea Exchange, the company’s fortunes are increasingly linked to the US biopharma environment through out-licensing deals and partnered assets like Rolvedon. For US investors who track global healthcare innovation, Hanmi provides insight into how Korean R&D capabilities feed into the American oncology and metabolic drug pipeline. The acquisition and subsequent sale of Rolvedon rights by US-based Assertio and Indian firm Zydus underscores the cross-border nature of value chains in oncology supportive care, as described in transaction coverage by Citeline as of 05/09/2024.

From a portfolio-construction standpoint, US-based investors can gain exposure to Hanmi either via direct investment on the Korean market, if their brokerage permits, or indirectly through global or Asia-focused healthcare funds that hold the stock. The risk-return profile differs from that of large US pharmaceutical companies: Hanmi’s reliance on milestones and royalties tied to specific partnered assets introduces event risk around clinical trial results, regulatory decisions and deal renegotiations. At the same time, the company benefits from a relatively diversified domestic product base and a growing ecosystem of affiliated businesses across pharmaceuticals and healthcare technology in Asia, as seen in initiatives such as JVM’s expansion described by The Chosun Ilbo as of 05/15/2026.

For US observers, Hanmi also serves as a case study in how regional innovation hubs outside the United States and Europe contribute to the global pipeline. Korean firms have built strong capabilities in long-acting formulations, biologics manufacturing and digital health, and partnerships with these companies can provide US pharma and biotech players with access to cost-effective R&D and differentiated technology platforms. The trajectory of Hanmi’s pipeline and partnerships may therefore offer broader insights into the evolving role of Korean biopharma in the global innovation landscape.

Risks and open questions

Hanmi Pharmaceutical’s strategy entails several notable risks. First, the company’s international growth prospects depend heavily on the success of partnered programs, which can be affected by factors beyond Hanmi’s direct control, including partners’ resource allocation decisions, competitive strategy and regulatory interactions in the US and Europe. Terminations or restructurings of licensing agreements, while common in the industry, can lead to volatility in expectations and, at times, in the company’s share price. The experience of shifting Rolvedon rights among multiple owners highlights how asset-level uncertainty can influence the timing and magnitude of Hanmi’s royalty streams, as seen in the Zydus–Assertio deal coverage by Citeline as of 05/09/2024.

Second, Hanmi operates in crowded therapeutic spaces where competition from global leaders is intense. In obesity and diabetes, for example, the company’s pipeline assets would need to demonstrate clear differentiation to secure attractive licensing terms and eventual commercial success. Similarly, in oncology supportive care, Rolvedon competes with entrenched alternatives, making market-share gains challenging. Finally, currency fluctuations between the Korean won and the US dollar can affect the translated value of royalty and milestone payments for international investors, while regulatory changes in Korea and abroad could impact pricing, reimbursement and investment in R&D. How Hanmi manages these uncertainties over the coming years will be a central question for investors monitoring the stock.

Conclusion

Hanmi Pharmaceutical stands out as a Korean drug developer whose commercial outlook is increasingly tied to the US pharmaceutical market through licensing deals and partnered products such as the oncology supportive care drug Rolvedon. The company combines a stable domestic prescription portfolio with a higher-risk, innovation-driven pipeline targeting oncology and metabolic disease, positioning itself as a partner to larger multinational firms. Recent developments around Rolvedon’s ownership and commercialization highlight both the opportunities and uncertainties inherent in Hanmi’s partnership model, while broader initiatives within the Hanmi ecosystem underscore a commitment to international growth. For US-focused investors following global healthcare, Hanmi offers a case study in cross-border value creation and the growing role of Korean biopharma in supplying assets to the US market, but the stock’s risk profile remains closely linked to clinical, regulatory and deal-related milestones.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.